A phase 1 study of oral loxo-292 in patients with advanced solid tumors, including ret-fusion non-small cell lung cancer, medullary thyroid cancer, and other tumors with increased ret activity
2017-000800-59Tumores sólidos avanzadosFundación Jiménez DíazInvestigador: Moreno García Víctor
